|Articles|March 5, 2008
DermTech adds Allan C. Halpern, M.D., to company's melanoma advisory board
Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.
Advertisement
La Jolla, Calif.
- Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.
DermTech is developing molecular diagnostics for the early detection of melanoma and other diseases. Dr. Halpern is a widely recognized expert in the early detection and management of melanoma in high-risk patients, the Times reports.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
